EUCTR2020-004617-12-AT进行中（未招募）1 期
INTEGRATE IIb - A Randomised Phase III Open Label Study of regorafenib + nivolumab vs standard chemotherapy in Refractory Advanced Gastro-Oesophageal Cancer (AGOC)
Australasian Gastro-Intestinal Trials Group (AGITG)0 个研究点目标入组 450 人开始时间: 2023年4月3日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 450
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Adults (18 years or over) with metastatic or locally recurrent gastro-oesophageal cancer which:
- •a. has arisen in any primary gastro-oesophageal site (oesophago-gastric junction (GOJ) or stomach); and
- •b. is of adenocarcinoma or undifferentiated carcinoma histology; and
- •c. is evaluable according to Response Evaluation Criteria in Solid Tumours (RECIST Version 1.1) by computed tomography (CT) scan performed
- •within 21 days prior to randomisation. A lesion in a previously irradiated area is eligible to be considered as measurable disease as long as
- •there is objective evidence of progression of the lesion prior to study enrolment; and
- •d. has failed or been intolerant to a minimum of 2 lines of prior anti-cancer therapy for recurrent/metastatic disease which must have included
- •at least one platinum agent and one fluoropyrimidine analogue. Note: Neoadjuvant or adjuvant chemotherapy or chemoradiotherapy will be
- •considered as first line treatment where people have relapsed or progressed within 6 months of completing treatment; Radiosensitising
- •chemotherapy given solely for this purpose concurrent with palliative radiation will not be considered as a line of treatment. Ramucirumab
- •monotherapy, or immunotherapy with a checkpoint inhibitor, will be considered a line of treatment.
- •e.HER2-positive participants must have received trastuzumab
- •2. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 (Appendix 1).
- •3. Ability to swallow oral medication.
- •4. Adequate bone marrow function (Platelets =100x109/L; Absolute Neutrophil Count (ANC) =1.5x109/L and Haemoglobin = 9.0g/dL).
- •5. Adequate renal function (Creatinine clearance >50 ml/min) based on either the Cockcroft-Gault formula (Appendix 2), 24-hour urine or Glomerular Filtration Rate (GFR) scan; and serum creatinine =1.5 x Upper Limit of Normal (ULN).
- •6. Adequate liver function (Serum total bilirubin =1.5 x ULN, and INR = 1.5 x ULN, and Alanine aminotransferase (ALT), Aspartate aminotransferase (AST), Alkaline phosphatase (ALP) =2.5 x ULN (= 5 x ULN for participants with liver metastases)).
- •Participants being treated with an anti-coagulant, such as warfarin or heparin, will be allowed to participate provided that no prior evidence of an
- •underlying abnormality in these parameters exists.
- •7. Willing and able to comply with all study requirements, including treatment, timing, and/or nature of required assessments and follow-up.
- •8. Study treatment both planned and able to start within 7 days after randomisation (note: subjects randomised on a Friday should commence
- •treatment no earlier than the following Monday)
- •9. Signed, written informed consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 225
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 225
排除标准
- •1. Known allergy to the investigational product drug class or excipients in the regorafenib and/or nivolumab
- •2. Poorly-controlled hypertension (systolic blood pressure >140mmHg or diastolic pressure> 90mmHg despite optimal medical management).
- •3. Participants with known, uncontrolled malabsorption syndromes
- •4. Any prior anti-VEGF targeted therapy using small molecule VEGF TKIs (e.g. apatinib). Prior anti-VEGF targeted monoclonal antibody therapies (e.g.
- •bevacizumab and ramucirumab) are permitted.
- •5. Any prior use of more than one immune checkpoint inhibitor
- •6. Treatment with any previous drug therapy within 2 weeks prior to first dose of study treatment. This includes any investigational therapy.
- •7. Use of biological response modifiers, such as granulocyte colony stimulating factor (G-CSF), within 3 weeks prior to randomisation.
- •8. Concurrent treatment with strong CYP3A4 inhibitors or inducers.
- •9. Palliative radiotherapy, unless more than 14 days have elapsed between completion of radiation and the date of registration, and adverse events resulting from radiation have resolved to < Grade 2 according to CTCAE V5.0
- •10. Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to randomization
- •11. Arterial thrombotic or ischaemic events, such as cerebrovascular accident, within 6 months prior to randomization.
- •12. Venous thrombotic events and pulmonary embolism within 3 months prior to randomization
- •13. Any haemorrhage or bleeding event = Grade 3 according to CTCAE v5.0 within 4 weeks prior to randomization.
- •14. Non-healing wound, ulcer, or bone fracture.
- •15. Interstitial lung disease with ongoing signs and symptoms
- •16. Clinical hyperthyroidism or hypothyroidism. Note: non-clinically significant abnormal TFTs (abnormal TSH and abnormal T3 and/or abnormal T4) considered to be due to sick euthyroid syndrome is allowed.
- •17.Persistent proteinuria of = Grade 3 according to CTCAE v5.0 (equivalent to > 3.5g of protein over 24 hour measured on either a random specimen or 24 hour collection.
- •18. Uncontrolled metastatic disease to the central nervous system. To be eligible, known CNS metastases should have been treated with surgery and/or radiotherapy and the patient should have been receiving a stable dose of steroids for at least 2 weeks prior to randomization, with no deterioration in neurological symptoms during this time.
- •19. History of another malignancy within 2 years prior to randomization. Participants with the following are eligible for this study:
- •a. curatively treated cervical carcinoma in situ,
- •b. non-melanomatous carcinoma of the skin,
- •c. superficial bladder tumours (T1a [Non-invasive tumour], and Tis [Carcinoma in situ]),
- •d. treated thyroid papillary cancer
- •20. Any significant active infection, including chronic active hepatitis B, hepatitis C, or HIV. Testing for these is not mandatory unless clinically indicated. Participants with known Hepatitis B/C infection will be allowed to participate providing evidence of viral suppression has been documented and the patient remains on appropriate anti-viral therapy.
- •21.Patients with acute coronary syndrome (including myocardial infarction and unstable angina), and with a history of coronary angioplasty or stent placement performed within 6 months before enrolment
- •22. Patients with a = grade 3 active infection according to CTCAE version 5.0
- •23. Patients with concurrent autoimmune disease, or a history of chronic or recurrent autoimmune disease
研究者
相似试验
进行中（未招募）
1 期
RegoNivo vs Standard of Care Chemotherapy in AGOC (INTEGRATEIIb)refractory, advanced gastro-oesophageal cancerMedDRA version: 20.1Level: PTClassification code: 10062878Term: Gastrooesophageal cancer Class: 100000004864CTIS2023-505441-69-00Institut fuer Klinische Krebsforschung IKF GmbH460
进行中（未招募）
1 期
A two part Open-Label, Randomized, Phase II/III clinical study to examine how safe and how well Dinutuximab works on it’s own or in combination with Irinotecan when treating patients with small cell lung cancer that is unresponsive or no longer responding to previous treatmentrelapsed or refractory small cell lung cancer (SCLC)MedDRA version: 21.1Level: PTClassification code 10041067Term: Small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-000758-20-SKnited Therapeutics Corporation485
进行中（未招募）
1 期
A two part Open-Label, Randomized, Phase II/III clinical study to examine how safe and how well Dinutuximab works on it’s own or in combination with Irinotecan when treating patients with small cell lung cancer that is unresponsive or no longer responding to previous treatmentrelapsed or refractory small cell lung cancer (SCLC)MedDRA version: 20.0Level: PTClassification code 10041067Term: Small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-000758-20-PLnited Therapeutics Corporation470
进行中（未招募）
1 期
A two part Open-Label, Randomized, Phase II/III clinical study to examine how safe and how well Dinutuximab works on it’s own or in combination with Irinotecan when treating patients with small cell lung cancer that is unresponsive or no longer responding to previous treatmentrelapsed or refractory small cell lung cancer (SCLC)MedDRA version: 20.0Level: PTClassification code 10041067Term: Small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-000758-20-HUnited Therapeutics Corporation470
进行中（未招募）
1 期
A two part Open-Label, Randomized, Phase II/III clinical study to examine how safe and how well Dinutuximab works on it’s own or in combination with Irinotecan when treating patients with small cell lung cancer that is unresponsive or no longer responding to previous treatmentrelapsed or refractory small cell lung cancer (SCLC)MedDRA version: 21.1Level: PTClassification code 10041067Term: Small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-000758-20-GBnited Therapeutics Corporation470